Navigation Links
Discovery could lead to a new animal model for hepatitis C
Date:1/28/2009

During its career, the potentially fatal hepatitis C virus has banked its success on a rather unusual strategy: its limitations. Its inability to infect animals other than humans and chimpanzees has severely hampered scientists in developing a useful small animal model for the disease. But now, in a breakthrough to be published in the January 29 advance online issue of Nature, Rockefeller University scientists have identified a protein that allows the virus to enter mouse cells, a finding that represents the clearest path yet for developing a much-needed vaccine as well as tailored treatments for the 170 million people across the globe living with the tenacious, insidious and rapidly changing virus.

By using a genetic screen, the group, led by Charles M. Rice, head of the Laboratory of Virology and Infectious Disease, identified a human protein, called occludin, that makes mouse cells susceptible to the virus. The discovery means that scientists now have the complete list of cellular factors a total of four that are required for the virus to enter nonhuman cells.

The hepatitis C virus exclusively targets human liver cells, suggesting that these cells express genes that allow uptake of the virus, genes that are not expressed in other human and nonhuman cells, explains Rice. In past years, three proteins CD81, CLDN1 and SR-BI were identified as having key roles in shuttling the virus into cells, but something was clearly missing. Rice's group found that even when they engineered mouse cells to overexpress all three proteins, the cells still denied the virus entry.

The discovery of occludin, however, has changed that. When Rice and his colleagues engineered mouse and human cell lines to express all four proteins, they showed that each cell line became infectible with the virus. To further establish occludin's role as a required entry factor, the group showed that human liver cells naturally express high levels of occludin, and
'/>"/>

Contact: Thania Benios
tbenios@rockefeller.edu
212-327-7146
Rockefeller University
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Discovery may help defang viruses
2. Stomach stem cell discovery could bring cancer insights
3. Symposium marks 30th anniversary of discovery of third domain of life
4. Emory paleontologist reports discovery of carnivorous dinosaur tracks in Australia
5. Natural product discovery by Cleveland medical researchers blocks tissue destruction
6. Researchers discovery may lead to hypertension treatment
7. Yale discovery suggests protein may play a role in severe asthma
8. Galapagos and Cystic Fibrosis Foundation Therapeutics announce drug discovery collaboration
9. Profound immune system discovery opens door to halting destruction of lupus
10. Scripps Research discovery leads to broad potential applications in CovX-Pfizer deal
11. New discovery could reduce the health risk of high-fat foods

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Discovery could lead to a new animal model for hepatitis C
Discovery could lead to a new animal model for hepatitis C
(Date:12/2/2009)..., , REDWOOD CITY, Calif., Dec. 2 /PRNews...rint identity and authentication solutions, today ...del of its DigitalPersona biometric fingerprint te...gitalPersona U.are.U® 4500HD offering allows ...kly identify users so that specific transactions c...
(Date:12/2/2009)..., , Before one of your muscles can twitch, before... nerve, a tiny floodgate of sortscalled an ion cha... organs to let in the chemical signals that spur t...nstitute of Standards and Technology (NIST) has al...e surface membrane for the first time, potentially...
(Date:12/2/2009)..., New York, NY, December 2, 2009 Commonly prescr...ment of asthma in pregnant women as well as pre-te...trum disorders, psychiatric pathology, cognitive p...ren, according to a new study published in the Dec...trics & Gynecology . , Beta 2 adrenergic agonist...
Breaking Biology News(10 mins):DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems 2Nervy research: Researchers take initial look at ion channels in a model system 2Treatments for asthma and pre-term labor may increase risk of autism in developing fetus 2IH Systems RIVA Top Pick for Directors of Pharmacy 57370 1IH Systems RIVA Top Pick for Directors of Pharmacy 57370 2HMS Awarded Third Party Liability Services Contract by Minnesota 57366 1Dr Drew and Drug Czar Host Online Chat 57362 1
...009) The Michael & Susan Dell Center for Advancem...chool of Public Health Austin Regional Campus will...eship in Child Health at 1:30 p.m. Thursday, April...e Center Amphitheater in Austin. , Obesity expe...biostatistics and epidemiology at the University o...
...astatic prostate cancer has shown considerable pro...hose disease has become resistant to current drugs...gues at several other institutions, including Memo... new drug to treat a particularly lethal form of t... cancer, or CRPC. Also referred to as hormone-refr...
...9, 2009 -- Four experts in soil carbon research, f...tunity farmers and foresters have to manage soil c...ate in voluntary markets. Agricultural and forest ...50 million metric tons of carbon dioxide (CO 2 ) e... gas emissions. , The briefing, "Down to Earth Ca...
Other Biology News:Annual Michael & Susan Dell lectureship in child health 2New drug shows promise in treating drug-resistant prostate cancer 2New drug shows promise in treating drug-resistant prostate cancer 3New drug shows promise in treating drug-resistant prostate cancer 4Down to Earth carbon science: Briefing April 15 in DC 2
(Date:12/2/2009)...SINGAPORE, Dec. 2 S*BIO Pte Ltd to... JAK2 inhibitor, SB1518, at The American Society o... New Orleans. ,, Data will be presented on the ...trial of SB1518 detailing its safety, tolerability...le in dose levels ranging from 100 to 600 mg. Thes...
(Date:12/2/2009)... SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world i...n turmoil and uncertainty is part of many,business...dustry has been,relatively immune to the economic ... , During the midst of the difficult time...; Johnson inaugurated an R&D center in Shangha...
(Date:12/1/2009)... VILLAGE, Nev., Dec. 1 P...nounced revenue guidance for the fourth quarter en..., as compared with $69 million for the fourth quar...ts was the first of two installment payments of $1... quarter 2008 results was a one-time $1.8 million ...
(Date:12/1/2009)...TH, Mass., Dec. 1 Harvest Technolo... results from the company sponsored 60-patient cli...enter in Chennai, India using the company,s BMAC S...ritical Limb Ischemia (CLI). Sri Ramachandra Medic...iated institution based in Chennai, India and one ...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3
...fications, thereby providing scientists with a too...duction to drug discovery. However, this sophistic...ing the threat of engineered pathogens. New resear...ome Biology shows that computational tools could b...ally engineered bacteria in environmental samples....
...ISE, Fla., March 17 Bioheart, Inc.,(Nasdaq: BHRT...elop,autologous (patient-derived) cell therapies a...heart damage, today announced that company founder...transition from Executive,Chairman and become Chai...,serves as the company,s Chief Technology Officer ...
...rch 19 at 10:00 AM EDT, CEDAR KNOLLS, N.J., March... today announced its financial results for,the fou...isphere will host a conference call to discuss fou...ch 19, 2008. A live webcast of the conference,call...: http://www.emisphere.com .,The live conference ...
Other Biology Technology:On the trail of rogue genetically modified pathogens 2Bioheart Founder, Howard J. Leonhardt, Becomes Chairman of the Board of Directors 2Bioheart Founder, Howard J. Leonhardt, Becomes Chairman of the Board of Directors 3Bioheart Founder, Howard J. Leonhardt, Becomes Chairman of the Board of Directors 4Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 2Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 3Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 4Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 5Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 6Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 7Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 8
Hybridization Buffer from BD Biosciences Pharmingen
Chicken Anti-Plants Thaumatin 2 Polyclonal Antibody, Unconjugated from Abcam
Proteinase K Buffer from BD Biosciences Pharmingen
Rabbit Anti-VEGF Receptor 2, phospho (Tyr1214) Polyclonal Antibody, Unconjugated from Abcam
Biology Products: